威高股份(01066.HK)控股股東威高集團公司擬配售6000萬股
格隆匯 6 月 23日丨威高股份(01066.HK)發佈公告,2020年6月22日,公司獲威高集團有限公司告知,其已訂立關於以每H股港幣15.07元的價格配售其持有的公司6000萬股H股的協議。
於該公佈日期,威高集團公司持有公司已發行股本約47.76%,而配售事項涉及的H股於該公佈日期佔公司的已發行股本約1.33%。於配售事項完成後,威高集團公司將仍為公司的控股股東,持有公司的已發行股本約46.43%。
公司亦已獲告知,威高集團公司擬將配售事項的所得款項淨額應用於其於醫療業務的投資,以及用於其營運的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.